October 27, 2015

Drs. Mino and Singh:

On behalf of American Society of Interventional Pain Physicians (ASIPP) and 51 state societies including Puerto Rico Society of Interventional Pain Physicians, we would like to thank you for requesting our input for Cigna Musculoskeletal Precertification Program. As you well know, we have corresponded with your organization in the past requesting consideration of multiple coverage issues with 684 signatures of interventional pain physicians from across the nation (see letter) and we would like to ensure that these procedures are provided appropriately and that patients insured by Cigna to maintain access to care. All our comments are based on evidence-based principles and available literature derived from randomized controlled trials and systematic reviews. In cases of lack of presence of randomized controlled trials, the evidence is derived from observational literature and consensus and we will state so.

ASIPP is a not-for-profit professional organization founded in 1998 now comprising over 4,500 interventional pain physicians and other practitioners who are dedicated to ensuring safe, appropriate and equal access to essential pain management services for patients across the country suffering with chronic and acute pain. There are approximately 8,500 appropriately trained and qualified physicians practicing interventional pain management in the United States.

Interventional pain management is defined as the discipline of medicine devoted to the diagnosis and treatment of pain related disorders principally with the application of interventional techniques in managing sub acute, chronic, persistent, and intractable pain, independently or in conjunction with other modalities of treatment (1).

Interventional pain management techniques are minimally invasive procedures, including percutaneous precision needle placement, with placement of drugs in targeted areas or ablation of targeted nerves; and some surgical techniques such as laser or endoscopic diskectomy, intrathecal infusion pumps and spinal cord stimulators, for the diagnosis and management of chronic, persistent or intractable pain (2).

Interventional pain management (09) also has been provided a mandatory membership to Carrier Advisory Committees (CACs) in each state in the United States (3).

The following are our concerns about Cigna Musculoskeletal Precertification Program and various issues related to the coverage policies. We will focus our comments on epidural injections, facet joint interventions, radiofrequency neurotomy, sacroiliac joint injections, facet joint injections and medial branch blocks, regional sympathetic blocks, and epidural adhesiolysis.

1.0 EPIDURAL STEROID INJECTIONS
The epidural steroid injections policy defines transforaminal epidural steroid injections, selective nerve root blocks, interlaminar epidural steroid injection, and caudal epidural injections. Further, the policy also defines radiculopathy with presence of pain and one or more of other signs including loss of strength, altered sensation, diminished or asymmetric reflexes, or concordant radiologist’s interpretation of an advanced diagnostic imaging study or electrodiagnostic studies.

The policy also defines spinal stenosis with pain distribution.

The changes we request based on evidence-based medical principles is that one or more of the following should include a positive straight leg raising or cross straight leg raising test (1).

• Loss of strength of specific muscle or myotomal distribution concordant with nerve root compression of the involved spinal nerve root may not cover straight leg raising. Straight leg raising may be present without evidence of loss of strength.
• Radiculopathy or radiculitis may also be caused secondary to chemical discs.

General Guidelines
The policy considers an epidural steroid injection administered for axial spinal pain without documentation of radiculopathy, myelopathy, or myeloradiculopathy is considered “not medically necessary” (2).

• Based on the available evidence, the policy should be changed to include axial or discogenic spinal pain after appropriate measures have been taken to rule out facet joint pain or sacroiliac joint pain with diagnostic blockade.

Systematic reviews and randomized controlled trials demonstrate efficacy of epidural injections in discogenic pain after elimination of facet joint pain (1-12).

• The policy states based on the fact that a caudal epidural steroid injection is not target specific, the injectate is diluted, and the injectate rarely reaches the level above L5-S1, a caudal epidural steroid injection for levels above L5-S1 without a supporting clinical rationale (why it is preferred over translaminar or transforaminal, e.g., status post fusion with anatomical limitations) for alternative approaches, is considered not medically necessary.
• This is not accurate in many cases, flow can be observed up to L4 or L3 levels. Even though post fusion with anatomical limitations permits this, this is not an accurate statement.

• The description says no more than 3 epidural steroid injections should be performed per episode of pain.

Further, this also describes a series of 3 injections.

• We support lack of evidence for series of 3 injections. There is no such benefit for any of the approaches with series of 3. We also support lack of evidence to support epidural steroid injection with ultrasound guidance for any indication.

• However, change of the number of injections will be appropriate. The average relief from an epidural injection in the early phases is approximately 3 weeks with the first procedure and for 6 weeks with the second procedure. Consequently, it will be more appropriate to divide and also improve the compliance with provision of 2 epidural injections during the diagnostic phase or initial phase within the first 3 months and restrict to 4 therapeutic injections per region per year thereafter (3-5,13).

Therapeutic Epidural Steroid Injections
An epidural steroid is considered medically necessary for presumed radiculopathy resulting from disease, injury or surgery that has not responded sufficiently to a reasonable course (four week minimum) of conservative treatment (exercise, physical methods including physical therapy and/or chiropractic care, NSAID’s and/or muscle relaxants).

• Once again, we would request to add proven discogenic pain after eliminating facet joint or sacroiliac joint pain if a patient has no facet joint or sacroiliac joint pain with axial pain will continue to suffer without any options if this is not included (1-12).

References
There has been substantial new literature which has not been included in these references. We suggest to add additional randomized controlled trials and systematic reviews published recently. With addition of these references, multiple old references can be deleted.


## 2.0 FACET JOINT INJECTIONS/MEDIAL BRANCH BLOCKS

Comments on facet joint injections and medial branch blocks are as follows:

1. **Facet joint injections/medial branch blocks**

   Even though generally 2 diagnostic blocks are required, your policy of one diagnostic block with 80% pain relief is acceptable, but it will increase false-positives and also will reduce outcomes with radiofrequency neurotomy.

2. **Therapeutic facet joint injections/medial branch blocks**

   The guidance reads that subsequent facet joint injections are considered there is no evidence, they are considered experimental, investigation, or unproven. These statements are inappropriate or unproven. There is significant evidence with randomized controlled trials, systematic reviews, and guidelines showing the effectiveness of therapeutic medial branch blocks similar to radiofrequency neurotomy. In fact, qualitative evidence synthesis showed Level II evidence for cervical, thoracic, and lumbar medial branch blocks based on randomized controlled trials (1-15); however, we agree with your assessment of intraarticular injections. There is only Level III evidence for intraarticular injections in the lumbar spine; however, some patients may require intraarticular injections and they do extremely well. These patients also may not be suitable for radiofrequency neurotomy.

   - Approval of medial branch blocks with appropriate consideration of clinical improvement of 2½ to 3 months will essentially be equal to expense wise or even more cost effective.
   - As you are aware, radiofrequency neurotomy costs twice than therapeutic medial branch blocks. If you approve one radiofrequency neurotomy for each 6 months, one in 3 months with therapeutic medial branch blocks will be more appropriate, less painful.
   - In the cervical spine, since radiofrequency neurotomy may not be performed bilaterally majority of the patients are receiving 2 procedures within the time period. This will be definitely cost savings to approve them.
   - Consequently we request the following language:

     If a patient experiences after initial 50% pain relief, at least 50% pain relief with improvement in functional status lasting at least 3 weeks a patient may be a candidate for therapeutic medial branch blocks. These blocks will be limited to 4 per year per region with documentation of 2½ to 3 months of relief with improvement in functional status.

**References**
The references appear to be somewhat outdated. There are multiple updated and recent references as shown here. With addition of these references, multiple old references can be deleted.


### 3.0 RADIOFREQUENCY JOINT ABLATIONS/DENERVATIONS

Majority of the guidance is appropriate except that 50% relief for 80% of the duration of the effect of the local anesthetic used appears to be contradicting the statement in medial branch blocks. It says 80% relief for diagnostic blocks. Further, this relief may increase false-positive rates significantly and decrease the efficacy. If 50% pain relief is used a diagnostic criteria, dual diagnostic blocks may be appropriate (1,2).
Based on the recent systematic review of therapeutic facet joint interventions with multiple trials included the evidence is Level II for radiofrequency neurotomy and therapeutic facet joint nerve blocks (3).

Once again we would request that therapeutic facet joint nerve blocks be added as an alternate modality to radiofrequency neurotomy. This will be a cost effective measure without increasing cost utility and at times reducing the cost utility.

References

The references appear to be somewhat outdated. There are multiple updated and recent references as shown here. With addition of these references, multiple old references can be deleted.


4.0 SACROILIAC JOINT INJECTIONS

The sacroiliac joint injection section includes the definitions of intraarticular sacroiliac joint injection, periarticular injection, and sacroiliac joint pain; however, it does not describe blockade of the nerve supply to the joint as well as therapeutic modalities with radiofrequency neurotomy.

Radiofrequency Neurotomy

Radiofrequency neurotomy as a therapeutic modality has not been described in this document. It may be appropriate to add to improve radiofrequency neurotomy with strict inclusion criteria with positive results with 2 diagnostic blocks and appropriate response for a repeat procedure.

There is emerging evidence for cooled radiofrequency neurotomy, even though it may be more expensive than traditional radiofrequency neurotomy. It is an option to be considered.

References

Appropriate references may be utilized with elimination of old and outdate references as shown in this manuscript.


5.0 REGIONAL SYMPATHETIC BLOCKS
Indications and Non-Indications

Indications and non-indications describe a maximum of 6 therapeutic blocks; however, some patients may require these on a long-term basis; consequently it may be essential to state that further blocks after initial 6 may be performed only with appropriate response of 2½ to 3 months with significant improvement with at least 50% pain relief and functional status improvement.

6.0 EPIDURAL ADHESIOLYSIS

Epidural adhesiolysis is shown as a non-covered procedure; however, there is substantial evidence even more than other procedures with multiple randomized controlled trials specifically in post lumbar surgery syndrome and spinal stenosis along with recalcitrant pain with degenerative disc disease with cost utility analysis showing appropriate cost effectiveness and clinical outcomes. It has been covered by medicare carriers ever since its inception and also it continues to be covered by medicare carriers throughout the United States.

The evidence synthesis utilizing strict criteria of methodologic quality assessment and clinically relevant outcomes shows Level II evidence for percutaneous adhesiolysis after failure of other modalities of treatments.

References

You may want to consider recent references and recent systematic reviews and update the references. With addition of these references, multiple old references can be deleted.


**AMERICAN SOCIETY OF INTERVENTIONAL PAIN PHYSICIANS**

**Laxmaiah Manchikanti, MD**  
Chairman of the Board and CEO, ASIPP  
Paducah, KY

**Peter Staats, MD**  
President, ASIPP  
Shrewsbury, NJ

**Ramsin M. Benyamin, MD**  
Immediate Past President, ASIPP  
Bloomington IL

**Aaron K. Calodney, MD**  
President-Elect, ASIPP  
Tyler TX

**Francis Riegler, MD**  
First Executive Vice President, ASIPP  
Palmdale, CA

**David A. Bryce, MD**  
Second Executive Vice President, ASIPP  
Madison, WI

**Sudhir Diwan, MD**  
Vice President of Strategic Planning, ASIPP  
New York, NY

**Harold Cordner, MD**  
Secretary, ASIPP  
Sebastian, FL

**Frank J.E. Falco, MD**  
Treasurer, ASIPP  
Philadelphia, PA

**DIRECTORS:**

**Salahadin Abdi, MD, PhD**  
Director-at-Large, ASIPP

**Steve Aydin, DO**
Young Physician Director, ASIPP

Cyrus E. Bakhit, MD
Lifetime Director, ASIPP

Sanjay Bakshi, MD
Director-at-Large, ASIPP

Mark V. Boswell, MD, PhD
Academic Director, ASIPP

Kaylea Boutwell, MD
Young Physician Director, ASIPP

Kenneth D. Candido, MD
AMA RUC Member

Christopher Gharibo, MD
Director-at-Large, ASIPP

Hans C. Hansen, MD
Director Emeritus

Standiford Helm, II, MD
Director Emeritus

Sachin “Sunny” Jha, MD
Resident/Fellow, ASIPP

Alan D. Kaye, MD, PhD
Academic Director, ASIPP

Dharam Mann, MD
Director-at-Large, ASIPP

Mikko Murakami, DO
Resident/Fellow, ASIPP

Devi E. Nampiaparimpil, MD
Young Physician Director, ASIPP

Sanford Silverman, MD
Director-at-Large, ASIPP

Vijay Singh, MD
Lifetime Director, ASIPP

Amol Soin, MD
Young Physician Director, ASIPP

STATE SOCIETIES OF INTERVENTIONAL PAIN PHYSICIANS:
Nancy Cross, MD  
President and CEO, Alaska Society of Interventional Pain Physicians

Patrick Hogan, DO  
President and CEO, Arizona Society of Interventional Pain Physicians

John Swicegood, MD  
President and CEO, Arkansas Society of Interventional Pain Physicians

Ray d’Amours, MD  
President and Executive Director, California Society of Interventional Pain Physicians

Kenneth C. Lewis, MD  
President and CEO, Colorado Society of Interventional Pain Physicians

Dean Mariano, DO  
President, Connecticut Pain Society

Alan Gonzalez-Cota, MD  
President and Executive Director, Delaware Society of Interventional Pain Physicians

Harold Dalton, DO  
President, Florida Society of Interventional Pain Physicians

David W. Gale, MD  
President, Georgia Society of Interventional Pain Physicians

Rudolph Puana, MD  
President, Hawaii Society of Interventional Pain Physicians

Holly Zoe, MD  
President, Idaho Society of Interventional Pain Physicians

James E. Wilson, MD  
President, Illinois Society of Interventional Pain Physicians

Mahendra Sanapati, MD  
President, Indiana Society of Interventional Pain Physicians

Bradley Wargo, DO  
President and CEO, Iowa Society of Interventional Pain Physicians

Mayank Gupta, MD  
President and CEO, Kansas Society of Interventional Pain Physicians

Ramarao Pasupuleti, MD  
President, Kentucky Society of Interventional Pain Physicians

Paul Hubbell, MD  
President and Executive Director, Society of Interventional Pain Physicians of Louisiana
Stephen Bamberger, MD  
President, Maine Society of Interventional Pain Physicians

Akil Benjamin, MD  
President, Maryland Society of Interventional Pain Physicians

Thomas Simopoulous, MD  
President and CEO, Massachusetts Society of Interventional Pain Physicians

Dennis Dobritt, DO  
President and CEO, Michigan Society of Interventional Pain Physicians

Andrew Will, MD  
President and CEO, Minnesota Society of Interventional Pain Physicians

Timothy Beacham, MD  
President, Mississippi Society of Interventional Pain Physicians

Kevin Coleman, MD  
President, Missouri Society of Interventional Pain Physicians

Scott Jahnke, DO  
President and CEO, Montana Society of Interventional Pain Physicians

Daniel Wik, MD  
President, Nebraska Society of Interventional Pain Physicians

Daniel E. Fabito, MD  
President, Nevada Society of Interventional Pain Physicians

George Lantz, DO  
President, New Hampshire Society of Interventional Pain Physicians

Peter Staats, MD  
President, New Jersey Society of Interventional Pain Physicians

Pamela O. Black, MD  
President and Executive Director, New Mexico Society of Interventional Pain Physicians

Christopher Gharibo, MD  
President, New York Carolina Society of Interventional Pain Physicians

Mark Hines, MD  
President, North Carolina Society of Interventional Pain Physicians

Rup K Nagala, MD  
President and CEO, North Dakota Society of Interventional Pain Physicians

Amol Soin, MD  
President and CEO, Ohio Society of Interventional Pain Physicians
Rico Guerra, MD  
President and CEO, Oklahoma Society of Interventional Pain Physicians

Peter Kosek, MD  
President, Oregon Society of Interventional Pain Physicians

Vahid Grami, MD, MPH  
President and CEO, Pennsylvania Society of Interventional Pain Physicians

Renier Mendez, MD  
Chief Executive Officer and President, Puerto Rico Society of Interventional Pain Physicians

Adrian Hamburger, MD  
President, Rhode Island Society of Interventional Pain Physicians

Ezra B. Riber, MD  
President and CEO, South Carolina Society of Interventional Pain Physicians

John Cook, MD  
President and CEO, South Dakota Society of Interventional Pain Physicians

Graf Hilgenhurst, MD  
President and Executive Director, Tennessee Society of Interventional Pain Physicians

Larry C. Driver, MD  
President, Texas Pain Society

Craig Davis, MD  
President and Executive Director, Utah Society of Interventional Pain Physicians

Evan Musman, DO  
President and Executive Director, Vermont Society of Interventional Pain Physicians

Douglas Wisor, MD  
President, Virginia Society of Interventional Pain Physicians

Arthur S. Watanabe, MD  
President, Washington Society of Interventional Pain Physicians

Timothy Deer, MD  
President, West Virginia Society of Interventional Pain Physicians

David A. Bryce, MD  
President, Wisconsin Society of Interventional Pain Physicians

Dan Alzheimer, MD  
President and CEO, Wyoming Society of Interventional Pain Physicians